Company intelligence / Profile preview

Progenics Pharmaceuticals

New York, New York, United Statesx.com ↗

Ownership: Public · LNTH
Employees: ~34
Development stage: Commercial

Overview

Progenics developed multiple oncology-focused therapeutics and diagnostics. Its radiotherapeutic AZEDRA was approved for rare neuroendocrine tumors. RELISTOR (methylnaltrexone bromide) was commercialized for opioid-induced constipation. The company advanced PSMA-targeted imaging agents and therapeutics into late-stage development or commercialization before its acquisition by Lantheus Holdings.

Therapeutic areas: GastroenterologyOncologyInfectious Diseases
Modalities: RadiopharmaceuticalMonoclonal antibodyAntibody-drug conjugateSmall molecule
Industry: Biotech

Partnerships

Salix/Bausch Health for RELISTOR licensingCytogen Corporation/JV on PSMA assets historicallyWyeth/Pfizer on methylnaltrexone development historically

Beyond the preview

Go deeper on Progenics Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Progenics Pharmaceuticals.

Explore the full profile